China’s medtech shake-up forces rethink on pricing, IP and innovation

A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

MedTech

Abbott clinches 18-country PI in glucose monitoring feud

9 September 2026 The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.

MedTech

Sun Pharma import ban back in force after Squires intervention

3 September 2026 A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.

MedTech

Abbott fends off Chinese rival’s patent challenge at UPC

18 August 2026 The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.

More features

Abbott clinches 18-country PI in glucose monitoring feud

UK firm hires head of IP with commercial and technical nous

Italy’s Biofer falls short in Fed Circ appeal over key claim wording

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

Sun Pharma import ban back in force after Squires intervention

10x Genomics wins latest round in Parse patent dispute

White & Case life sciences co-leader moves firms

China’s medtech shake-up forces rethink on pricing, IP and innovation

More on this story

Editor's picks

Editor's picks

More features